Investigating how a protein involved in inflammation may contribute to brain diseases like Alzheimer's and Parkinson's.
ASC oligomerization and transmission as an initiating event for protein aggregation in Synucleinopathy Dementias
['FUNDING_OTHER'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-10899456
This study is looking at how a protein called ASC affects the development of brain diseases like Alzheimer's and Parkinson's, and it hopes to find new ways to help patients by understanding how this protein interacts with another one that contributes to brain damage.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-10899456 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a specific protein, ASC, in the progression of Synucleinopathy Dementias, which include Alzheimer's and Parkinson's diseases. The study examines how ASC, released by immune cells in the brain, may influence the aggregation of another protein, α-Synuclein, leading to neurodegeneration. By using advanced models, researchers aim to uncover the mechanisms behind this process and its implications for disease progression. Patients may benefit from insights that could lead to new therapeutic strategies targeting these pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with Synucleinopathy Dementias, including Alzheimer's Disease and Parkinson's Disease with Dementia.
Not a fit: Patients with other forms of dementia not related to Synucleinopathy may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent the progression of neurodegenerative diseases like Alzheimer's and Parkinson's.
How similar studies have performed: Previous research has shown promising results in understanding the role of neuroinflammation in neurodegenerative diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PANICKER, NIKHIL — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: PANICKER, NIKHIL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome